Parkinson's Trial NCT07308795
Assess expiratory respiratory muscle strength
- Trial ID
- NCT07308795
- Official Title
- The Ultrasonographic Evaluation of Abdominal Accessory Respiratory Muscle Thickness in Patients With Parkinson's Disease: Correlation With Disease Severity and Expiratory Respiratory Muscle Strength
- Goal
- Assess expiratory respiratory muscle strength
- Status
- RECRUITING
- Sponsor
- Istanbul Physical Medicine Rehabilitation Training and Research Hospital
- Study Type
- OBSERVATIONAL
- Enrollment
- 36 participants
- Conditions
- Parkinson Disease (PD), Maximum Inspiratory Pressure, Maximum Expiratory Pressure, Abdominal Accessory Respiratory Muscle Thickness
Summary For Families
The goal is to find out whether thinner abdominal accessory breathing muscles, seen on ultrasound, are linked to worse Parkinson's severity and to weaker inhaling and exhaling pressures. The team uses noninvasive ultrasound to measure those muscle thicknesses and standard mouth-pressure tests called maximum inspiratory pressure and maximum expiratory pressure to see if muscle loss matches lower breathing strength, which could help flag respiratory problems earlier and guide breathing-focused care. Adults 18 to 75 with Parkinson's at Hoehn and Yahr stages 1,3, MMSE over 23, and BMI under 30 can join, while active smokers, people with active chest disease or unstable vitals, those whose Parkinson's is not controlled with medication, and Parkinson-plus syndromes are excluded.
Locations
- İstanbul Fizik Tedavi Ve Rehabilitasyon Eğitim Ve Araştirma Hastanesi, Istanbul, BAHÇELİEVLER, Turkey (Türkiye)
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to find out whether thinner abdominal accessory breathing muscles, seen on ultrasound, are linked to worse Parkinson's severity and to weaker inhaling and exhaling pressures. The team uses noninvasive ultrasound to measure those muscle thicknesses and standard mouth-pressure tests called maximum inspiratory pressure and maximum expiratory pressure to see if muscle loss matches lower breathing strength, which could help flag respiratory problems earlier and guide breathing-focused care. Adults 18 to 75 with Parkinson's at Hoehn and Yahr stages 1,3, MMSE over 23, and BMI under 30 can join, while active smokers, people with active chest disease or unstable vitals, those whose Parkinson's is not controlled with medication, and Parkinson-plus syndromes are excluded.
- Who can participate?
- Participants must be between 18 Years and 75 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 2 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.